布地格福吸入气雾剂治疗急性加重高风险慢性阻塞性肺疾病患者的疗效

doi:10.3969/j.issn.1671-7171.2024.09.020

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1210 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要【目的】探讨布地格福吸入气雾剂治疗急性加重高风险慢性阻塞性肺疾病(COPD)的疗效及其安全性。【方法】160 例急性加重高风险 COPD 患者,随机分为观察组(布地格福吸入气雾剂治疗)和对照组(茚达特罗格隆溴铵吸入粉雾剂用胶囊治疗),每组80例。比较两组患者治疗前及治疗后3个月、6个月的肺功能指标、血气指标、COPD评估测试(CAT)评分、呼吸困难指数(mMRC)评分、运动耐力[6 min步行距离(6MWD)]、生命质量(SGRQ)评分。【结果】治疗3个月、6个月后,观察组患者的肺功能指标、血气指标明显优于对照组(P<0.05);观察组的mMRC评分、CAT评分以及SGRQ量表中的呼吸症状评分低于对照组(P<0.05),6MWD大于对照组(P<0.05),而两组SGRQ量表中的日常活动、疾病症状评分及总分比较,差异无统计学意义(P>0.05);两组不良反应总发生率比较,差异无统计学意义(P>0.05)。【结论】布地格福吸入气雾剂治疗急性加重高风险COPD患者的疗效好,且不增加药物不良反应的发生率。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	朱艳竞
	陈培杰
	纪小丽
	朱利芹

关键词 ：肺疾病,慢性阻塞性/药物疗法, 支气管扩张药/药理学, 治疗结果

Abstract：【Objective】To investigate the efficacy and safety of Budesonide-Formoterol inhalation aerosol in treating high-risk acute exacerbations of chronic obstructive pulmonary disease (COPD).【Methods】A total of 160 patients with high-risk acute exacerbations of COPD were randomly divided into the observation group (treated with Budesonide-Formoterol inhalation aerosol) and the control group (treated with Indacaterol-Glycopyrronium inhalation powder capsules), with 80 cases in each group. The differences in pulmonary function indicators, blood gas indicators, COPD assessment test (CAT) scores, modified Medical Research Council (mMRC) dyspnea scale scores, exercise endurance [six-minute walk distance (6MWD)] and quality of life (SGRQ) scores before treatment, and at 3 months and 6 months after treatment were compared between the two groups.【Results】 After 3 and 6 months of treatment, the pulmonary function indicators and blood gas indicators of the observation group were significantly better than those of the control group (P<0.05). The mMRC, CAT, and respiratory symptom scores in the SGRQ scale of the observation group were lower than those of the control group (P<0.05), and the 6MWD was higher than that of the control group (P<0.05). However, there was no statistically significant difference in daily activities, disease symptoms, and total scores on the SGRQ scale between the two groups (P>0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05).【Conclusion】 Budesonide-Formoterol inhalation aerosol is effective in treating high-risk acute exacerbations of COPD and it does not increase the incidence of adverse drug reactions.

Key words： Pulmonary Disease, Chronic Obstructive/DT Bronchodilator Agents/PD Treatment Outcome

收稿日期: 2023-12-20

中图分类号:

R563

通讯作者: * E-mail:zzm95752829@163.com

引用本文:

朱艳竞, 陈培杰, 纪小丽, 朱利芹. 布地格福吸入气雾剂治疗急性加重高风险慢性阻塞性肺疾病患者的疗效[J]. 医学临床研究, 2024, 41(9): 1354-1357.
ZHU Yanjing, CHEN Peijie, JI Xiaoli, et al. Efficacy of Budesonide-Formoterol Inhalation Aerosol in Treating High-Risk Acute Exacerbations of Chronic Obstructive Pulmonary Disease Patients. JOURNAL OF CLINICAL RESEARCH, 2024, 41(9): 1354-1357.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.09.020 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I9/1354

[1] HALPIN D M G, CRINER G J, PAPI A, et al. Global Initiative for the diagnosis, management, and prevention of chronic obstructive lung disease:the 2020 GOLD science committee report on COVID-19 & COPD[J].Am J Respir Crit Care Med,2021,203(1):24-36.
[2] HURST J R, VESTBO J, ANZUETO A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease[J].N Engl J Med,2010,363(12):1128-1138.
[3] KLAUS F RABE F J M G, BALLAL S, MCLAREN J, et al.Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD[J].N Engl J Med,2020,383(1):35-48.
[4] MALERBA M, NARDIN M, SANTINI G, et al. Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD:the current evidence base and future prospects[J].Ther Adv Respir Dis,2018,12(2):102-104.
[5] GARY T FERGUSON K F R F, WANG C, ICHINOSE M, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS):a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial[J].Lancet Respir Med,2018,6(10):747-758.
[6] LIU Y, SHI H, SUN X, et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in COPD:a meta-analysis[J].Eur J Intern Med,2014,25(5):491-495.
[7] 姚剑坤, 李翠君, 欧阳细瑜, 等. 布地格福吸入气雾剂联合肺康复训练对中重度慢阻肺患者的影响[J].中国实用医药, 2022,17(6):29-32.
[8] ROJAS-REYES M X, MORALES O M G, DENNIS R J, et al. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease[J].Cochrane Database Syst Rev,2016(6):D8532.
[9] 范晓艳. 布地格福吸入气雾剂对慢性阻塞性肺疾病急性加重期患者的疗效分析[J].中国药物与临床, 2021,21(24):3994-3997.
[10] 张妍琦, 李鑫, 孙璐, 等. 布地格福吸入气雾剂治疗中、重度支气管哮喘患者的临床研究[J].中国临床药理学杂志, 2022,38(1):3-5.
[11] 郑笑红. 布地格福吸入气雾剂治疗重度慢性阻塞性肺疾病的效果研究[J].中外医学研究, 2023,21(9):13-16.
[12] 孟现玲, 何玉廷, 毛若琳, 等. 圣乔治呼吸问卷、CAT及mMRC评分在慢性阻塞性肺病中的应用[J].复旦学报(医学版), 2022,49(6):862-868.
[13] HANANIA N A, SETHI S, KOLTUN A, et al. Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD[J].Int J Chron Obstruct Pulmon Dis,2019,14:117-127.
[14] BRAVE H, MACLOUGHLIN R. State of the art review of cell therapy in the treatment of lung disease, and the potential for aerosol delivery[J].Int J Mol Sci,2020,21(17):6435.